title: 5-HT2C receptor modulators: a patent survey.
abstract: BACKGROUND
  The 5-HT(2C) receptor is a GPCR and is one of the 14 subtypes that constitute the serotonin receptor family. The 5-HT₂(C) receptor is exclusively expressed in the CNS where it demonstrates a wide distribution and displays high-affinity interactions with a wide variety of psychiatric medications. Modulators of 5-HT₂(C) have been implicated as a potential treatment for diseases of significant unmet medical need, including obesity, schizophrenia, depression, anxiety, Parkinson's disease, drug addiction, erectile dysfunction and urinary incontinence. Thus, there is a great interest in developing potent and selective 5-HT₂(C) receptor modulators.
  
  
  METHODS
  This review article highlights the research progress in 5-HT₂(C) receptor modulators published in the patent literature between January 2003 and June 2010, giving emphasis to the medicinal chemist's standpoint.
  
  
  RESULTS
  Readers will rapidly gain an overview of the various 5-HT₂(C) receptor modulators reported in the patent literature in the past 8 years. Furthermore, the readers will learn which structure type can interact with the 5-HT₂(C) receptor. In addition, the readers will be aware of the pharmaceutical companies that have been the main players in the field.
  
  
  CONCLUSIONS
  There is substantial evidence supporting the concept that a selective 5-HT₂(C) receptor modulator should provide benefit in the treatment of a variety of CNS disorders. Although research efforts have identified several promising 5-HT₂(C) receptor modulators that display high functional selectivity, further clinical efficacy and safety data are needed to prove their actual clinical utility. Therefore, the query for selectively acting 5-HT₂(C) receptor modulators is still ongoing.
authors.affiliation: Green Cross Corporation, Research Center, Giheung-Gu, Yongin, Gyeonggi-Do, 446-770, Republic of Korea.
authors.forename: Junwon
authors.initials: J
authors.lastname: Lee
authors.forename: Myung Eun
authors.initials: ME
authors.lastname: Jung
authors.forename: Jinhwa
authors.initials: J
authors.lastname: Lee
mesh_terms: D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry; D054314:Drug Inverse Agonism; D006801:Humans; D010330:Patents as Topic; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects* / Q000378:metabolism; D058826:Serotonin 5-HT2 Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology*; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists